

Andrew J Massey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526919/publications.pdf>

Version: 2024-02-01

45
papers

2,826
citations

236925

25
h-index

265206

42
g-index

47
all docs

47
docs citations

47
times ranked

3705
citing authors

#	ARTICLE	IF	CITATIONS
1	4,5-Diarylisoazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 196-218.	6.4	386
2	A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 535-545.	2.3	272
3	Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4212-4215.	6.4	232
4	Novel Adenosine-Derived Inhibitors of 70 kDa Heat Shock Protein, Discovered Through Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1510-1513.	6.4	205
5	NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. <i>Breast Cancer Research</i> , 2008, 10, R33.	5.0	191
6	Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3- <i>d</i>]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4794-4809.	6.4	157
7	Photoactivation of DNA thiobases as a potential novel therapeutic option. <i>Current Biology</i> , 2001, 11, 1142-1146.	3.9	103
8	Adenosine-Derived Inhibitors of 78 kDa Glucose Regulated Protein (Grp78) ATPase: Insights into Isoform Selectivity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4034-4041.	6.4	94
9	Structure-based discovery of a new class of Hsp90 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5187-5191.	2.2	87
10	Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. <i>BMC Cancer</i> , 2014, 14, 570.	2.6	84
11	3-(5-chloro-2,4-dihydroxyphenyl)-Pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5197-5201.	2.2	83
12	Knockdown of PAK4 or PAK1 Inhibits the Proliferation of Mutant KRAS Colon Cancer Cells Independently of RAF/MEK/ERK and PI3K/AKT Signaling. <i>Molecular Cancer Research</i> , 2013, 11, 109-121.	3.4	83
13	4-Amino derivatives of the Hsp90 inhibitor CCT018159. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2543-2548.	2.2	79
14	Adenine derived inhibitors of the molecular chaperone HSP90's SAR explained through multiple X-ray structures. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 325-328.	2.2	69
15	ATPases as Drug Targets: Insights from Heat Shock Proteins 70 and 90. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7280-7286.	6.4	67
16	Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 906-919.	4.1	54
17	Targeting Hsp90 for the treatment of cancer. <i>Current Opinion in Drug Discovery & Development</i> , 2006, 9, 483-95.	1.9	51
18	Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells. <i>Molecular Cancer</i> , 2014, 13, 147.	19.2	45

#	ARTICLE	IF	CITATIONS
19	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6770-6789.	3.0	40
20	Identification of novel, <i>in vivo</i> active Chk1 inhibitors utilizing structure guided drug design. <i>Oncotarget</i> , 2015, 6, 35797-35812.	1.8	38
21	DNA mismatch repair and acquired cisplatin resistance in <i>E. coli</i> and human ovarian carcinoma cells. <i>DNA Repair</i> , 2003, 2, 73-89.	2.8	33
22	Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC. <i>PLoS ONE</i> , 2015, 10, e0134306.	2.5	33
23	^3H 2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. <i>BMC Cancer</i> , 2014, 14, 483.	2.6	30
24	Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening. <i>Topics in Current Chemistry</i> , 2011, 317, 61-82.	4.0	29
25	Ambiguous coding is required for the lethal interaction between methylated DNA bases and DNA mismatch repair. <i>DNA Repair</i> , 2002, 1, 275-286.	2.8	26
26	Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8971-8991.	6.4	26
27	4-Thio-5-bromo-2-deoxyuridine: chemical synthesis and therapeutic potential of UVA-induced DNA damage. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 995-997.	2.2	24
28	Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6745-6764.	6.4	23
29	Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2487-2495.	4.1	22
30	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2271-2286.	6.4	22
31	A high content, high throughput cellular thermal stability assay for measuring drug-target engagement in living cells. <i>PLoS ONE</i> , 2018, 13, e0195050.	2.5	22
32	Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells. <i>FEBS Journal</i> , 2021, 288, 4507-4540.	4.7	22
33	mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. <i>Molecular Oncology</i> , 2016, 10, 101-112.	4.6	17
34	Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy. <i>Cancer Letters</i> , 2016, 383, 41-52.	7.2	16
35	Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. <i>Oncotarget</i> , 2016, 7, 85033-85048.	1.8	16
36	Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage. <i>Scientific Reports</i> , 2017, 7, 40778.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor. PLoS ONE, 2010, 5, e13123.	2.5	11
38	Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma. Journal of Cellular and Molecular Medicine, 2021, 25, 10650-10662.	3.6	7
39	Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells. DNA Repair, 2021, 101, 103099.	2.8	4
40	Checkpoint Kinase 1 (Chk1) inhibition fails to activate the Stimulator of Interferon Genes (STING) innate immune signalling in a human coculture cancer system. Molecular Biomedicine, 2021, 2, 19.	4.4	3
41	Abstract 4458: Chk1 inhibition as a novel therapeutic strategy for treating triple negative breast and ovarian cancers. , 2011, , .		3
42	Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity. Scientific Reports, 2016, 6, 35874.	3.3	2
43	Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discovery, 2018, 23, 144-153.	2.7	2
44	Abstract A212: A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor-induced apoptosis in HCT116 colon carcinoma cells. , 2009, , .		1
45	Abstract C207: Checkpoint abrogation and potentiation of cytotoxic chemotherapeutics with a novel checkpoint kinase 1 inhibitor. , 2009, , .		0